<?xml version='1.0' encoding='utf-8'?>
<document id="26309401"><sentence text="Effects of amoxicillin/clavulanic acid on the pharmacokinetics of valproic acid."><entity charOffset="11-22" id="DDI-PubMed.26309401.s1.e0" text="amoxicillin" /><entity charOffset="23-38" id="DDI-PubMed.26309401.s1.e1" text="clavulanic acid" /><entity charOffset="66-79" id="DDI-PubMed.26309401.s1.e2" text="valproic acid" /><pair ddi="false" e1="DDI-PubMed.26309401.s1.e0" e2="DDI-PubMed.26309401.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26309401.s1.e0" e2="DDI-PubMed.26309401.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26309401.s1.e0" e2="DDI-PubMed.26309401.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26309401.s1.e1" e2="DDI-PubMed.26309401.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26309401.s1.e1" e2="DDI-PubMed.26309401.s1.e2" /></sentence><sentence text="Valproic acid (VPA) is mainly metabolized via glucuronide, which is hydrolyzed by β-glucuronidase and undergoes enterohepatic circulation"><entity charOffset="0-13" id="DDI-PubMed.26309401.s2.e0" text="Valproic acid" /><entity charOffset="15-18" id="DDI-PubMed.26309401.s2.e1" text="VPA" /><entity charOffset="46-57" id="DDI-PubMed.26309401.s2.e2" text="glucuronide" /><pair ddi="false" e1="DDI-PubMed.26309401.s2.e0" e2="DDI-PubMed.26309401.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26309401.s2.e0" e2="DDI-PubMed.26309401.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26309401.s2.e0" e2="DDI-PubMed.26309401.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26309401.s2.e1" e2="DDI-PubMed.26309401.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26309401.s2.e1" e2="DDI-PubMed.26309401.s2.e2" /></sentence><sentence text=" Amoxicillin/clavulanic acid (AMC) administration leads to decreased levels of β-glucuronidase-producing bacteria, suggesting that these antibiotics could interrupt enterohepatic circulation and thereby alter the pharmacokinetics of VPA"><entity charOffset="1-12" id="DDI-PubMed.26309401.s3.e0" text="Amoxicillin" /><entity charOffset="13-28" id="DDI-PubMed.26309401.s3.e1" text="clavulanic acid" /><entity charOffset="30-33" id="DDI-PubMed.26309401.s3.e2" text="AMC" /><entity charOffset="233-235" id="DDI-PubMed.26309401.s3.e3" text="VPA" /><pair ddi="false" e1="DDI-PubMed.26309401.s3.e0" e2="DDI-PubMed.26309401.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26309401.s3.e0" e2="DDI-PubMed.26309401.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26309401.s3.e0" e2="DDI-PubMed.26309401.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26309401.s3.e0" e2="DDI-PubMed.26309401.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26309401.s3.e1" e2="DDI-PubMed.26309401.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26309401.s3.e1" e2="DDI-PubMed.26309401.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26309401.s3.e1" e2="DDI-PubMed.26309401.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26309401.s3.e2" e2="DDI-PubMed.26309401.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26309401.s3.e2" e2="DDI-PubMed.26309401.s3.e3" /></sentence><sentence text=" This study aimed to evaluate the effects of AMC on the pharmacokinetics of VPA"><entity charOffset="76-79" id="DDI-PubMed.26309401.s4.e0" text="VPA" /><entity charOffset="45-47" id="DDI-PubMed.26309401.s4.e1" text="AMC" /><pair ddi="false" e1="DDI-PubMed.26309401.s4.e1" e2="DDI-PubMed.26309401.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26309401.s4.e1" e2="DDI-PubMed.26309401.s4.e0" /></sentence><sentence text=" This was an open-label, two-treatment, one-sequence study in 16 healthy volunteers" /><sentence text=" Two treatments were evaluated; treatment VPA, in which a single dose of VPA 500 mg was administered, and treatment AMC + VPA, in which multiple doses of AMC 500/125 mg were administered three times daily for 7 days and then a single dose of VPA was administered"><entity charOffset="73-76" id="DDI-PubMed.26309401.s6.e0" text="VPA" /><entity charOffset="242-245" id="DDI-PubMed.26309401.s6.e1" text="VPA" /><entity charOffset="42-44" id="DDI-PubMed.26309401.s6.e2" text="VPA" /><entity charOffset="122-124" id="DDI-PubMed.26309401.s6.e3" text="VPA" /><entity charOffset="116-118" id="DDI-PubMed.26309401.s6.e4" text="AMC" /><entity charOffset="154-156" id="DDI-PubMed.26309401.s6.e5" text="AMC" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e2" e2="DDI-PubMed.26309401.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e2" e2="DDI-PubMed.26309401.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e2" e2="DDI-PubMed.26309401.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e2" e2="DDI-PubMed.26309401.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e2" e2="DDI-PubMed.26309401.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e2" e2="DDI-PubMed.26309401.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e0" e2="DDI-PubMed.26309401.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e0" e2="DDI-PubMed.26309401.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e0" e2="DDI-PubMed.26309401.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e0" e2="DDI-PubMed.26309401.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e0" e2="DDI-PubMed.26309401.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e4" e2="DDI-PubMed.26309401.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e4" e2="DDI-PubMed.26309401.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e4" e2="DDI-PubMed.26309401.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e4" e2="DDI-PubMed.26309401.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e3" e2="DDI-PubMed.26309401.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e3" e2="DDI-PubMed.26309401.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e3" e2="DDI-PubMed.26309401.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e5" e2="DDI-PubMed.26309401.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26309401.s6.e5" e2="DDI-PubMed.26309401.s6.e1" /></sentence><sentence text=" Blood samples were collected up to 48 hours" /><sentence text=" Pharmacokinetic parameters were calculated using noncompartmental methods" /><sentence text=" Fifteen subjects completed the study" /><sentence text=" Systemic exposures and peak concentrations of VPA were slightly lower with treatment AMC + VPA than with treatment VPA (AUClast, 851"><entity charOffset="47-49" id="DDI-PubMed.26309401.s10.e0" text="VPA" /><entity charOffset="92-94" id="DDI-PubMed.26309401.s10.e1" text="VPA" /><entity charOffset="116-118" id="DDI-PubMed.26309401.s10.e2" text="VPA" /><entity charOffset="86-88" id="DDI-PubMed.26309401.s10.e3" text="AMC" /><pair ddi="false" e1="DDI-PubMed.26309401.s10.e0" e2="DDI-PubMed.26309401.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26309401.s10.e0" e2="DDI-PubMed.26309401.s10.e3" /><pair ddi="false" e1="DDI-PubMed.26309401.s10.e0" e2="DDI-PubMed.26309401.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26309401.s10.e0" e2="DDI-PubMed.26309401.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26309401.s10.e3" e2="DDI-PubMed.26309401.s10.e3" /><pair ddi="false" e1="DDI-PubMed.26309401.s10.e3" e2="DDI-PubMed.26309401.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26309401.s10.e3" e2="DDI-PubMed.26309401.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26309401.s10.e1" e2="DDI-PubMed.26309401.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26309401.s10.e1" e2="DDI-PubMed.26309401.s10.e2" /></sentence><sentence text="0 h·mg/L vs 889" /><sentence text="6 h·mg/L; C max, 52" /><sentence text="1 mg/L vs 53" /><sentence text="0 mg/L)" /><sentence text=" There were no significant between-treatment effects on pharmacokinetics (95% confidence interval [CI]) of AUClast and C max (95" /><sentence text="7 [85" /><sentence text="9-106" /><sentence text="5] and 98" /><sentence text="3 [91" /><sentence text="6-105" /><sentence text="6], respectively)" /><sentence text=" Multiple doses of AMC had no significant effects on the pharmacokinetics of VPA; thus, no dose adjustment is necessary"><entity charOffset="77-79" id="DDI-PubMed.26309401.s22.e0" text="VPA" /><entity charOffset="19-21" id="DDI-PubMed.26309401.s22.e1" text="AMC" /><pair ddi="false" e1="DDI-PubMed.26309401.s22.e1" e2="DDI-PubMed.26309401.s22.e1" /><pair ddi="false" e1="DDI-PubMed.26309401.s22.e1" e2="DDI-PubMed.26309401.s22.e0" /></sentence><sentence text=" " /></document>